Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In the SUSTAIN clinical trial program, the average HbA1c reductions ranged from 1.45% to 1.55%, depending on the dose (0.5 mg to 1 mg weekly)
If your Current Weight is: Your new weight could be: Average study participant lost 15% *In the STEP 5 trial, participants for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, patients taking semaglutide (typically in doses of 2.4 mg once weekly) for weight management lost an average of about 15% of their body weight over 68 weeks
GLP-1 agonists reduce blood pressure in people without diabetes through direct vascular mechanisms, not just blood sugar control
It would also assist in further weight loss or reduction in other medications to reduce polypharmacy. Oral semaglutide is only currently approved for treating type 2 diabetes, with only two GLP-1-related injectables liraglutide and Wegovy approved for treating obesity
US$ 28.61
US$ 20.76
US$ 29.11
US$ 27.12
US$ 22.09
US$ 20.23
US$ 28.16
US$ 21.70
US$ 29.96
US$ 22.02
US$ 27.38
